

---

## 6. Bibliography

- Adjei, A.L., 1997.** Clinical development of inhaled peptides and proteins. In: Adjei, A.L., Gupta, P.K. (Eds.), *Inhalation delivery of therapeutic peptides and proteins*. Marcel Dekker Inc., New York, pp 771-814.
- Adjei, A.L., Gupta, P., 1998.** Pulmonary delivery of therapeutic peptides and proteins. *J. Contr. Rel.* 29, 361-373.
- Adriaens, E., Dierckens, K., Bauters, T.G.M., Nelis, H.J., van Goethem, F., Vanparys, P., Remon, J.P., 2001.** The mucosal toxicity of different benzalkoniumchloride analogues evaluated with an alternative test using slugs. *Pharm. Res.* 18(7), 937-942.
- Agu, R.U., Dang, H.V., Jorissen, M., Willems, T., Kinget, R., Verbeke, N., 2002.** Nasal absorption enhancement strategies for therapeutic peptides: an in vitro study using cultured human nasal epithelium. *Int. J. Pharm.* 237(1-2), 179-191.
- Ahsan, F., Arnold, J., Meezan, E., Pillion, D.J., 2001.** Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats. *Pharm. Res.* 18(12), 1742-1746.
- Aikawa, K., Mitsutake, N., Uda, H., Tanaka, S., Shimamura, H., Aramaki, Y., Tsuchiya, S., 1998.** Drug release from pH-response polyvinylacetal diethylamino acetate hydrogel and application to nasal delivery. *Int. J. Pharm.* 168(2), 181-188.
- Aikawa, K., Matsumoto, K., Mitsutake, N., Uda, H., Tanaka, S., Shimamura, H., Aramaki, Y., Tsuchiya, S., 2002.** Drug release from pH-response polymer to nasal delivery. *STP Pharma Sci.* 12(1), 69-74.
- Akahane, T., Kawashima, S., Hirao, I., Shimizu, T., Minakata, A., 1982.** Ion selectivities of some extracellular viscous polysaccharides from red algae. *Polymer Journal (Tokyo, Japan)* 14(3), 181-188.
- Almeida, A.J., Alpar, H.O., Brown, M.R.W., 1993.** Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(L-lactic acid) microspheres in rats, rabbits and guinea pigs. *J. Pharm. Pharmacol.* 45(3), 198-203.
- Alvarez, F., Faundes, A., Johansson, E., Coutinho, E., 1983.** Blood levels of levonorgestrel in women following vaginal placement of contraceptive pills. *Fertil. Steril.* 40(1), 120-123.
- Andersen, I., Proctor, D.F., 1983.** Measurement of nasal mucociliary clearance. *Eur. J. Respir. Dis. Suppl.* 127, 37-40.
- Anggard, A., 1974.** Capillary and shunt blood flow in the nasal mucosa of the cat. *Acta Otolaryngol.* 78(5-6), 418-422.
- Artursson, P., Lindmark, T., Davis, S.S., Illum, L., 1994.** Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). *Pharm. Res.* 11(9), 1358-1361.

- Asai, K., Morishita, M., Katsuta, H., Hosoda, S., Shinomiya, K., Noro, M., Nagai, T., Takayama, K., 2002.** The effects of water-soluble cyclodextrins on the histological integrity of the rat nasal mucosa. *Int. J. Pharm.* 246, 25-35.
- Aspden, T.J., Mason, J.D.T., Jones, N.S., Lowe, J., Skaugrud, O., Illum, L., 1997.** Chitosan as a nasal delivery system: The effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. *J. Pharm. Sci.* 86, 509-513.
- Atsuta, S., Majima, Y., 1998.** Nasal mucociliary clearance of chronic sinusitis in relation to rheological properties of nasal mucus. *Ann. Otol. Rhinol. Laryngol.* 107(1), 47-51.
- Audus, K.L., Tavakoli-Saberi, M.R., 1991.** Aminopeptidases of newborn bovine nasal turbinate epithelial cell cultures. *Int. J. Pharm.* 76(3), 247-255.
- Aungst, B.J., Rogers, N.J., Schefter, E., 1988.** Comparison of nasal, rectal, buccal, sublingual and intramuscular insulin efficacy and the effects of a bile salt absorption promoter. *J. Pharmacol. Exp. Ther.* 244(1), 23-28.
- Azria, M., 1986.** Solid nasal drug insert. *Ger. Offen.* DE 3617728.
- Bacon, A., Makin, J., Sizer, P.J., Jabbal-Gill, I., Hinchcliffe, M., Illum, L., Chatfield, S., Roberts, M., 2000.** Carbohydrate biopolymers enhance antibody response to mucosally delivered vaccine antigens. *Infect. Immun.* 68(10), 5764-5770.
- Bally, M.B., Harvie, P., Wong, F.M.P., Kong, S., Wasan, E.K., Reimer, D.L., 1999.** Biological barriers to cellular delivery of lipid-based DNA carriers. *Adv. Drug Deliv. Rev.* 38(3), 291-315.
- Banga, A.K., Chien, Y.W., 1988.** Systemic delivery of therapeutic peptides and proteins. *Int. J. Pharm.* 48(1-3), 15-50.
- Barchfeld, G.L., Hessler, A.L., Chen, M., Pizza, M., Rappuoli, R., Van Nest, G.A., 1999.** The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. *Vaccine* 17(7-8), 695-704.
- Bascom, R., Kesavanathan, J., Fitzgerald, T.K., Cheng, K.H., Swift, D.L., 1995.** Sidestream tobacco smoke exposure acutely alters human nasal mucociliary clearance. *Environ. Health Persp.* 103(11), 1026-1030.
- Batts, A.H., Marriott, C., Martin, G.P., Bond, S.W., 1989.** The effect of some preservatives used in nasal preparations on mucociliary clearance. *J. Pharm. Pharmacol.* 41, 156-159.
- Bende, M., Flisberg, K., Larsson, I., Ohlin, P., Olsson, P., 1983.** A method for determination of blood flow with <sup>133</sup>Xe in human nasal mucosa. *Acta Otolaryngol.* 96(3-4), 277-285.
- Benziger, D.P., Edelson, J., 1983.** Absorption from the vagina. *Drug Metab. Rev.* 14(2), 137-168.
- Berendes, J., Link, R., Zöllner, F., 1977.** Hals-Nasen-Ohren-Heilkunde in Praxis und Klinik: Obere und untere Luftwege I. Thieme-Verlag, Stuttgart, Chapter 2, 10, 11, 16.
- Berna Biotech AG press release.** 14.09.2001. Berna Biotech AG decides not to market Nasalflu during the current flu season. Bern, Switzerland.
- Bernkop-Schnürch, A., 2000.** Method for improving the mucoadhesion of polymers. Austrian patent AT 406054.

- Bernkop-Schnürch**, A., Kast, C.E., Richter, M.F., **2001**. Improvement in the mucoadhesive properties of alginate by the covalent attachment of cysteine. *J. Contr. Rel.* 71, 277-285.
- Bernkop-Schnürch**, A., Hornof, M., Zoidl, T., **2003**. Thiolated polymers - thiomers: synthesis and in vitro evaluation of chitosan-2-iminothiolane conjugates. *Int. J. Pharm.* 260(2), 229-237.
- Berstad**, A.K., Andersen, S.R., Dalseg, R., Dromtorp, S., Holst, J., Namork, E., Wedege, E., Haneberg, B., **2000**. Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine. *Vaccine* 18(18), 1910-1919.
- Bibby**, D.C., Davies, N.M., Tucker, I.G., **2000**. Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. *Int. J. Pharm.* 197, 1-11.
- Bird**, A.P., Faltinek, J.R., Shoajaei, A.H., **2001**. Transbuccal peptide delivery: stability and in vitro permeation studies on endomorphin-1. *J. Contr. Rel.* 73, 31-36.
- Björk**, E., Edman, P., **1990**. Characterization of degradable starch microspheres as a nasal delivery system for drugs. *Int. J. Pharm.* 62, 187-192.
- Björk**, E., Isaksson, U., Edman, P., Artursson, P., **1995**. Starch microspheres induce pulsatile delivery of drugs and peptides across the epithelial barrier by reversible separation of the tight junctions. *J. Drug Targ.* 2(6), 501-507.
- Blouin**, J.L., Meeks, M., Radhakrishna, U., Sainsbury, A., Gehring, C., Sail G.D., Bartoloni, L., Dombi, V., O'Rawe, A., Walne, A., Chung, E., Afzelius, B.A., Armengot, M., Jorissen, M., Schidlow, D.V., van Maldergem, L., Walt, H., Gardiner, R.M., Probst, D., Guerne, P.A., Delozier-Blanchet, C.D., Antonarakis, S.E., **2000**. Primary ciliary dyskinesia: a genome-wide linkage analysis reveals extensive locus heterogeneity. *Eur. J. Hum. Genet.* 8(2), 109-118.
- Bodmeier**, R., Maincent, P., **1999**. Zubereitungen mit verlängerter Verweildauer am Applikationsort. Ger. Offen. DE 19756314.
- Bommer**, R., **1999**. Advances in nasal drug delivery technology. *Pharmaceutical Technology Europe* 11, 26-33
- Bond**, S.W., Hardy, J.G., Wilson, C.G., **1984**. Deposition and clearance of nasal sprays. *Biopharm. Pharmacokinet., Eur. Congr.*, 2nd, 93-98.
- Borchard**, G., Lueßen, H.L., de Boer, A.G., Verhoef, J.C., Lehr, C.-M., Junginger, H.E., **1996**. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. *J. Contr. Rel.* 39, 131-138.
- Boulmedarat**, L., Grossiord, J.L., Fattal, E., Bochot, A., **2003**. Influence of methyl- $\beta$ -cyclodextrin and liposomes on rheological properties of Carbopol 974P NF gels. *Int. J. Pharm.* 254(1), 59-64.
- Brewster**, M.E., Estes, K.S., Loftsson, T., Perchalski, R., Derendorf, H., Mullersman, G., Bodor, N., **1988**. Improved delivery through biological membranes: Solubilization and stabilization of an estradiol chemical delivery system by modified beta-cyclodextrins. *J. Pharm. Sci.* 77(11), 981-985.
- Brittebo**, E.B., **1982**. N-Demethylation of aminopyrine by the nasal mucosa in mice and rats. *Acta Pharmacol. Tox.* 51(3), 227-232.

- Bucolo, C., Maltese, A., Puglisi, G., Pignatello, R., 2002.** Enhanced ocular anti-inflammatory activity of ibuprofen carried by an Eudragit RS100 nanoparticle suspension. *Ophthalmic Research* 34(5), 319-323.
- Bühler, V., 1999.** Kollidon® - Polyvinylpyrrolidone for the pharmaceutical industry. 4<sup>th</sup> Ed., BASF AG, Ludwigshafen.
- Bulletti, C., De Ziegler, D., Giacomucci, E., Polli, V., Rossi, S., Alfieri, S., Flamini, C., 1997.** Vaginal drug delivery: the first uterine pass effect. *Ann. NY Acad. Sci.* 828, 285-290.
- Burt, D.S., Lowell, G.H., White, G.L., Fries, L.F., Torossian, K., Jones, D.H., Plante, M. 2001.** Proteosome influenza vaccine. *PCT Int. Appl. WO 0160402.*
- Caliceti, P., Veronese, F.M., Lora, S., 2000.** Polyphosphazene microspheres for insulin delivery. *Int. J. Pharm.* 211, 57-65.
- Callens, C., Remon, J.P., 2000.** Evaluation of starch-maltodextrin-Carbopol® 974 P mixtures for the nasal delivery of insulin in rabbits. *J. Contr. Rel.* 66, 215-220.
- Callens, C., Ceulemans J., Ludwig, A., Foreman, P., Remon, J.P., 2003a.** Rheological study on mucoadhesivity of some nasal powder formulations. *Eur. J. Pharm. Biopharm.* 55, 323-328.
- Callens, C., Pringels, E., Remon, J.P., 2003b.** Influence of multiple nasal administrations of bioadhesive powders on the insulin bioavailability. *Int. J. Pharm.* 250, 415-422.
- Ceulemans, J., Vermeire, A., Adriaens, E., Remon, J.P., Ludwig, A., 2001.** Evaluation of a mucoadhesive tablet for ocular use. *J. Contr. Rel.* 77, 333-344.
- Chen, R.-H., Chang, J.-R., Shyur, J.-S., 1997.** Effects of ultrasonic conditions and storage in acidic solutions on changes in molecular weight and polydispersity of treated chitosan solutions. *Carbohydr. Res.* 299, 287-294.
- Chetoni, P., Di Colo, G., Grandi, M., Morelli, M., Saettone, M.F., Darougar, S., 1998.** Silicone rubber / hydrogel composite ophthalmic inserts: preparation and preliminary in vitro / in vivo evaluation. *Eur. J. Pharm. Biopharm.* 46, 125-132.
- Chickering, D.E., Mathiowitz, E., 1999.** Definitions, Mechanisms, and Theories of bioadhesion. In: Mathiowitz, E., Chickering, D.E., Lehr, C.-M. (Eds.), *Bioadhesive drug delivery systems. Fundamentals, novel approaches, and development.* Marcel Dekker Inc., New York, pp. 1-10.
- Chi, E.Y., Krishnan, S., Randolph, T.W., Carpenter, J.F., 2003.** Physical stability of proteins in aqueous solution: mechanism and driving forces in non-native protein aggregation. *Pharm. Res.* 20, 1325-1336.
- Chien, Y.W., 1995.** Biopharmaceutics basis for transmucosal delivery. *S.T.P. Pharma Sci.* 5(4), 257-275.
- Chow, H.-H.S., Anavy, N., Villalobos, A., 2001.** Direct nose-brain transport of benzoylecgonine following intranasal administration in rats. *J. Pharm. Sci.* 90(11), 1729-1735.
- Christie, C.D., Hanzal, R.F., 1931.** Insulin absorption by the conjunctival membranes in rabbits. *J. Clin. Invest.* 10, 787-793.
- Cicinelli, E., Cignarelli, M., Sabatelli, S., Romano, F., Schonauer, L.M., Padovano R., Einer-Jensen, N., 1998.** Plasma concentrations of progesterone are higher in the uterine artery than in the radial artery after vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. *Fertil. Steril.* 69(3), 471-473.

- Clark, M.A., Hirst, B.H., Jepson, M.A., 2000.** Lectin-mediated mucosal delivery of drugs and microparticles. *Adv. Drug Deliv. Rev.* 43, 207-223.
- Clausen, A.E., Kast, C.E., Bernkop-Schnürch, A., 2002.** The role of glutathione in the permeation enhancing effect of thiolated polymers. *Pharm. Res.* 19, 602-608.
- Colombo, P., Conte, U., Gazzaniga, A., Maggi, L., Sangalli, M.E., Peppas, N.A., La Manna, A., 1990.** Drug release modulation by physical restriction of the matrix swelling. *Int. J. Pharm.* 63, 43-48.
- Colombo, P., Catellani, P.L., Peppas, N.A., Maggi, L., Conte, U., 1992.** Swelling characteristics of hydrophilic matrices for controlled release: New dimensionless number to describe the swelling and release behavior. *Int. J. Pharm.* 88, 99-109.
- Corbo, D.C., Liu, J.C., Chien, Y.W., 1990.** Characterization of the barrier properties of mucosal membranes. *J. Pharm. Sci.* 79(3), 202-206.
- Crowder, T.M., Rosati, J.A., Schroeter, J.D., Hickey, A.J., Martonen, T.B., 2002.** Fundamental effects of particle morphology on lung delivery: Predictions of Stokes' Law and the particular relevance to dry powder inhaler formulation and development. *Pharm. Res.* 19(3), 239-245.
- Dahlin, M., Jansson, B., Bjork, E., 2001.** Levels of dopamine in blood and brain following nasal administration to rats. *Eur. J. Pharm. Sci.* 14(1), 75-80.
- Dale, O., Hoffer, C., Sheffels, P., Kharasch, E.D., 2002.** Disposition of nasal, intravenous, and oral methadone in healthy volunteers. *Clin. Pharmacol. Therap.* 72, 536-545.
- Davis, S.S., 1999.** Delivery of peptide and non-peptide drugs through the respiratory tract. *Pharm. Sci Technol. To.* 2(11), 450-456.
- Davis, S.S., 2001.** Nasal Vaccines. *Adv. Drug Deliv. Rev.* 51, 21-42.
- de Boer, A.G., Breimer, D.D., 1997.** Hepatic first-pass effect and controlled drug delivery following rectal administration. *Adv. Drug Deliv. Rev.* 28(2), 229-237.
- de Haan, A., Geerligs, H.J., Huchshorn, J.P., van Scharrenburg, G.J.M., Palache, A.M., Wilschut, J., 1995.** Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an co-administered liposomes. *Vaccine* 13, 155-162.
- de Leede, L.G.J., de Boer, A.G., Poertzgen, E., Feijen, J., Breimer, D.D., 1986.** Rate-controlled rectal drug delivery in man with a hydrogel preparation. *J. Contr. Rel.* 4, 17-24.
- De Ponti, R., Lardini, E., 1991.** Use of chemical enhancers for nasal drug delivery. *Drug Dev. Ind. Pharm.* 17(11), 1419-1436.
- Di Colo, G., Burgalassi, S., Chetoni, P., Fiaschi, M.P., Zambito, Y., Saettone, M.F., 2001.** Gel-forming erodible inserts for ocular controlled delivery of ofloxacin. *Int. J. Pharm.* 215, 101-111.
- Di Colo, G., Zambito, Y., Burgalassi, S., Serafini, A., Saettone, M.F., 2002.** Effect of chitosan on in vitro release and ocular delivery of ofloxacin from erodible inserts based on poly(ethylene oxide). *Int. J. Pharm.* 248, 115-122.
- Diestelhorst, M., Grunethal, S., Süverkrüp, R., 1999.** Dry Drops: a new preservative-free drug delivery system. *Graefe's Arch. Clin. Exp. Ophthalmol.* 237, 394-398.
- Dondeti, P., Zia, H., Needham, T.E., 1996.** Bioadhesive and formulation parameters affecting nasal absorption. *Int. J. Pharm.* 127, 115-133.

- Donovan**, M.D., Flynn, G.L., Amidon, G.L., **1990**. The molecular weight dependence of nasal absorption: The effect of absorption enhancers. *Pharm. Res.* 7(8), 808-815.
- Duchateau**, G.S., Graamans, K., Zuidema, J., Merkus, F.W., **1985**. Correlation between nasal ciliary beat frequency and mucus transport rate in volunteers. *Laryngoscope* 95, 854-859.
- Duchêne**, D., Touchard, F., Peppas, N.A., **1988**. Pharmaceutical and medical aspects of bioadhesive systems for drug administration. *Drug Dev. Ind. Pharm.* 14, 283-318.
- Dufes**, C., Olivier, J.-C., Gaillard, F., Gaillard, A., Couet, W., Muller, J.-M., **2003**. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. *Int. J. Pharm.* 255, 87-97.
- Dürig**, T., Fassihi, R., **2002**. Guar-based monolithic matrix systems: effect of ionizable and non-ionizable substances and excipients on gel dynamics and release kinetics. *J. Contr. Rel.*, 80, 45-56.
- Dyer**, A.M., Hinchcliffe, M., Watts, P., Castile, J., Jabbal-Gill, I., Nankervis, R., Smith, A., Illum, L., **2002**. Nasal delivery of insulin using novel chitosan based formulations: A comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. *Pharm. Res.* 19, 998-1008.
- Edman**, P., Björk, E., Rydén, L., **1992**. Microspheres as a nasal delivery system for peptide drugs. *J. Contr. Rel.* 21, 165-172.
- Edwards**, D.A., Hanes, J., Caponetti, G., Hrkach, J., Ben-Jebria, A., Eskew, M.L., Mintzes, J., Deaver, D., Lotan, N., Langer, R., **1997**. Large porous particles for pulmonary drug delivery. *Science* 276, 1868-1871.
- Edwards**, D.A., Ben-Jebria, A., Langer, R., **1998**. Recent advances in pulmonary drug delivery using large, porous inhaled particles. *J. Appl. Physiol.* 85(2), 379-385.
- Eerikainen**, S., Leino, J., Harjula, M., Klinge, E., Marvola, M., **1996**. Use of a hard gelatin capsule as a rectal dosage form. *S.T.P. Pharma Sci.* 6, 435-440.
- Eich**, G., Krähenbühl, S., Fückiger, U., **2001**. Nasalflu Berna: intranasaler, inaktivierter Grippeimpfstoff. *Schweiz. Med. Forum* 10, 260-262.
- El Kharraz**, K., Dashevsky, A., Bodmeier, R., **2003**. Microparticles prepared by grinding of polymeric films. *J. Microencapsul.* 20, 661-673.
- Faller**, A., **1988**. *Der Körper des Menschen – Einführung in Bau und Funktion*. 11<sup>th</sup> Ed., Georg Thieme Verlag Stuttgart – New York, 232 – 236.
- Ferguson**, J.L., McCaffrey, T.V., Kern, E.B., Martin, W.J. 2<sup>nd</sup>, **1988**. The effects of sinus bacteria on human ciliated nasal epithelium in vitro. *Otolaryng. Head Neck* 98(4), 299-304.
- Fernández-Urrusuno**, R., Calvo, P., Remuñán-López, C., Vila-Jato, J.L., Alonso, M.J., **1999**. Enhancement of nasal absorption of insulin using chitosan nanoparticles. *Pharm. Res.* 16, 1576-1581.
- Filipovic-Grcic**, J., Becirevic-Lacan, M., Skalko, N., Jalsenjak, I., **1996**. Chitosan microspheres of nifedipine and nifedipine-cyclodextrin inclusion complexes. *Int. J. Pharm.* 135, 183-190.
- Fridriksdóttir**, H., Loftsson, T., Gudmundsson, J.A., Bjarnason, G.J., Kjeld, M., Thorsteinsson, T., **1996**. Design and in vivo testing of 17 $\beta$ -estradiol-HP $\beta$ CD sublingual tablets. *Pharmazie* 51, 39-42.

- Fries, L.F., Montemarano, A.D., Mallett, C.P., Taylor, D.N., Hale, T.L., Lowell, G.H., 2001.** Safety and immunogenicity of a proteosome-*Shigella flexneri* 2a lipopolysaccharide vaccine administered intranasally to healthy adults. *Infect. Immun.* 69(7), 4545-4553.
- Frömming, K.-H., Szejtli, J., 1994.** Cyclodextrins in pharmacy. Kluwer Academic Publishers, Dordrecht, p 189.
- Gallichan, W.S., Rosenthal, K.L., 1995.** Specific secretory immune response in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. *Vaccine* 13, 1589-1595.
- Gibson, H.W., Liu, S., Gong, C., Ji, Q., Joseph, E., 1997.** Studies of the formation of poly(ester rotaxane)s from diacid chlorides, diols, and crown ethers and their properties. *Macromolecules* 30(13), 3711-3727.
- Gizurarson, S., 1990.** Animal models for intranasal drug delivery studies: a review article. *Acta Pharm. Nordica* 2(2), 105-122.
- Gizurarson, S., Aggerbeck, H., Árnadóttir, S.G., Mordhorst, C.H., Heron, I., 1996.** Intranasal vaccination against influenza using pharmaceutical excipients as immunological adjuvants. *Vaccine Res.* 5, 69-75.
- Gizurarson, S., Aggerbeck, H., Gudmundsson, M., Heron, I., 1998.** Intranasal vaccination: pharmaceutical evaluation of the vaccine delivery system and immunokinetic characteristics of the immune responses. *Pharm. Dev. Technol.* 3, 385-394.
- Glueck, R., 2001.** Review of intranasal influenza vaccine. *Adv. Drug Deliv. Rev.* 51, 203-211.
- Gonda, I., 2000.** The ascent of pulmonary drug delivery. *J. Pharm. Sci.* 89 (7), 940-945.
- Gong, C., Balanda, P.B., Gibson, H.W., 1998.** Supramolecular chemistry with macromolecules: New self-assembly based main chain polypseudorotaxanes and their properties. *Macromolecules* 31, 5278-5289.
- Grass, G.M., Robinson, J.R., 1988.** Mechanism of corneal drug penetration II: Ultrastructural analysis of potential pathways for drug movement. *J. Pharm. Sci.* 77, 15-23.
- Greer, C.E., Petracca, R., Buonamassa, D.T., Di Tommaso, A., Gervase, B., Reeve, R.L., Ugozzoli, M., Van Nest, G., De Magistris, M.T., Bensi, G., 2001.** The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunization with human papillomavirus type 6b (HPV-6b) virus-like particles. *Vaccine* 19(9-10), 1008-1012.
- Gupta, V.K., Hariharan, M., Wheatley, T.A., Price, J.C., 2001.** Controlled-release tablets from carrageenans: effect of formulation, storage and dissolution factors. *Eur. J. Pharm. Biopharm.* 51(3), 241-248.
- Gudmundsdottir, H., Sigurjonsdottir, J.F., Masson, M., Fjalldal, O., Stefansson, E., Loftsson, T., 2001.** Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans. *Pharmazie* 56(12), 963-966.
- Gutierrez de Rubalcava, C., Rodriguez, J.L., Duro, R., Alvarez-Lorenzo, C., Concheiro, A., Seijo, B., 2000.** Interactions between liposomes and hydroxypropyl methyl cellulose. *Int. J. Pharm.* 203(1-2), 99-108.
- Guy, B., Pascal, N., Françon, A., Bonnin, A., Gimenez, S., Lafay-Vialon, E., Trannoy, E., Haensler, J., 2001.** Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. *Vaccine* 19, 1794-1805.

- Hacker**, E., Kossowicz, J., Milde, K., **1991**. The protection of insulin against proteolytic processes after rectal application to normoglycemic rabbits. *Pharmazie* 46(2), 125-127.
- Hagiwara**, Y., Tsuji, T., Iwasaki, T., Kadowaki, S., Asanuma, H., Chen, Z., Komase, K., Suzuki, Y., Aizawa, C., Kurata, T., Tamura, S., **2001**. Effectiveness and safety of mutant *Escherichia coli* heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine. *Vaccine* 19(15-16), 2071-2079.
- Hamman**, J.H., Stander, M., Junginger, H.E., Kotze, A.F., **2000**. Enhancement of paracellular drug transport across mucosal epithelial by N-trimethylchitosan chloride. *STP Pharma Sci.* 10, 35-38.
- Harada**, A., **1997**. Construction of supramolecular structures from cyclodextrins and polymers. *Carbohydr. Polym.* 34, 183-188.
- Hardy**, J.G., Lee, S.W., Wilson, C.G., **1985**. Intranasal drug delivery by spray and drops. *J. Pharm. Pharmacol.* 37, 294-297.
- Harris**, A.S., Nilsson, I.M., Wagener, Z.G., Alkner, U., **1986**. Intranasal administration of peptides: nasal deposition, biological response and absorption of desmopressin. *J. Pharm. Sci.* 75, 1085-1088.
- Harris**, A.S., Svensson, E., Wagner, Z.G., Lethagen, S., Nilsson, I.M., **1988**. Effect of viscosity on particle size, deposition and clearance of nasal delivery systems containing desmopressin. *J. Pharm. Sci.* 77, 405-408.
- Harris**, A.S., Ohlin, M., Svensson, E., Lethagen, S., Nilsson, I.M., **1989**. Effect of viscosity on the pharmacokinetics and biological response to intranasal desmopressin. *J. Pharm. Sci.* 78, 470-471.
- Hascicek**, C., Gönül, N., Erk, N., **2003**. Mucoadhesive microspheres containing gentamicin sulphate for nasal administration: preparation and in vitro characterization. *Il Farmaco*, 58, 11-16.
- Hayashi**, M., Hirasawa, T., Muraoka, T., Shiga, M., Awazu, S., **1985**. Comparison of water influx and sieving coefficient in rat jejunal, rectal, and nasal absorption of antipyrine. *Chem. Pharm. Bull.* 33, 2149-2152.
- Hercules Inc.**, **1997**. GENU<sup>®</sup> carrageenan – general description. Product information.
- Hersey**, S.J., Jackson, R.T., **1987**. Effect of bile salts on nasal permeability in vitro. *J. Pharm. Sci.* 76(12), 876-879.
- Hinchliffe**, M., Illum, L., **1999**. Intranasal insulin delivery and therapy. *Adv. Drug Deliv. Rev.* 35, 199-234.
- Hirai**, S., Yashiki, T., Mima, H., **1981**. Mechanisms for the enhancement of the nasal absorption of insulin by surfactants. *Int. J. Pharm.* 9(2), 173-184.
- Hladon**, T., Cwiertnia, B., **1994**. Physical and chemical interactions between cellulose ethers and  $\beta$ -cyclodextrins. *Pharmazie* 49, 497-500.
- Ho**, N.F., Suhardja, L., Hwang, S., Owada, E., Molokhia, A., Flynn, G.L., Higuchi, W.I., Park, J.Y., **1976**. Systems approach to vaginal delivery of drugs III: Simulation studies interfacing steroid release from silicone matrix and vaginal absorption in rabbits. *J. Pharm. Sci.* 65(11), 1578-1585.



- Honkanen**, H., Ranta, S., Ylikorkala, O., Heikinheimo, O., **2002**. The kinetics of serum hCG and progesterone in response to oral and vaginal administration of misoprostol during medical termination of early pregnancy. *Hum. Reprod.* 17(9), 2315-2319.
- Hoogstraate**, J.A.J., Wertz, P.W., **1998**. Drug delivery via the buccal mucosa. *Pharm. Sci. Technol. To.* 1(7), 309-316.
- Hornof**, M., Weyenberg, W., Ludwig, A., Bernkop-Schnürch, A., **2003**. Mucoadhesive ocular insert based on thiolated poly(acrylic acid): development and in vivo evaluation in humans. *J. Contr. Rel.* 89(3), 419-428.
- Hussain**, A., Foster, T., Hirai, S., Kashihara, T., Batenhorst, R., Jones, M., **1980**. Nasal absorption of propranolol in humans. *J. Pharm. Sci.* 69(10), 1240-1242.
- Hussain**, A.A., Dakkuri, A., Itoh, S., **2000**. Nasal absorption of ondansetron in rats: an alternative route of drug delivery. *Cancer Chemoth. Pharm.* 45, 432-434.
- Hussain**, A.A., Dittert, L.W., **2001**. Intranasal administration of raloxifen and tamoxifen. *PCT Int. Appl.* WO 0135946.
- Illum**, L., Jorgensen, H., Bisgaard, H., Krogsgaard, O., Rossing, N., **1987**. Bioadhesive microspheres as a potential nasal drug delivery system. *Int. J. Pharm.* 39, 189-199.
- Illum**, L., Farraj, N.F., Johansen, B.R., O'Hagan, D.T., **1990**. Investigation of the nasal absorption of biosynthetic human growth hormone in sheep – use of bioadhesive microsphere delivery system. *Int. J. Pharm.* 63, 207-211.
- Illum**, L., Farraj, N.F., Fisher, A.N., Gill, I., Miglietta, M., Benedetti, L.M., **1994a**. Hyaluronic acid ester microspheres as a nasal delivery system for insulin. *J. Contr. Rel.* 29, 133-141.
- Illum**, L., **1994b**. Nasal drug delivery composition containing nicotine. *PCT Int. Appl.* WO 9427576.
- Illum**, L., **1996**. Nasal delivery. The use of animal models to predict performance in man. *J. Drug Target.* 3(6), 427-442.
- Illum**, L., Fisher, A.N., **1997**. Intranasal delivery of peptides and proteins. In: Adjei, A.L., Gupta, P.K. (Eds.), *Inhalation delivery of therapeutic peptides and proteins*. Marcel Dekker Inc., New York, pp. 135-184.
- Illum**, L., **1999**. Bioadhesive formulations for nasal peptide delivery. In: Mathiowitz, E., Lehr, C.M., Chickering, D. (Eds.), *Bioadhesive drug delivery systems: Fundamentals, novel approaches and development*. Marcel Dekker Inc., New York, pp. 507-539.
- Illum**, L., **2000a**. Transport of drugs from the nasal cavity to the central nervous system. *Eur. J. Pharm. Sci.* 11(1), 1-18.
- Illum**, L., Watts, P., Fisher, A.N., Jabbal-Gill, I., Davis, S.S., **2000b**. Novel chitosan based delivery system for nasal administration of a LHRH-analogue. *STP Pharma Sci.* 10, 89-94.
- Illum**, L., **2001**. Nasal vaccination: a non-invasive vaccine delivery method that holds great promise for the future. *Adv. Drug Deliv. Rev.* 51, 1-3.
- Illum**, L., **2003**. Nasal drug delivery – possibilities, problems and solutions. *J. Contr. Rel.* 87, 187-198.
- Inagaki**, M., Sakakura, Y., Itoh, H., Ukai, K., Miyoshi, Y., **1985**. Macromolecular permeability of the tight junction of the human nasal mucosa. *Rhinology* 23(3), 213-221.

- Irie, T., Wakamatsu, K., Arima, H., Aritomi, H., Uekama, K., 1992.** Enhancing effects of cyclodextrins on nasal absorption of insulin in rats. *Int. J. Pharm.* 84(2), 129-39.
- Irie, T., Uekama, K., 1999.** Cyclodextrins in peptide and protein delivery. *Adv. Drug Deliv. Rev.* 36, 101-123.
- Irwin, W.J., Holbrook, P.A., Dey, M.J., 1995.** The stability of peptides in nasal enzymic systems. *Int. J. Pharm.* 113(1), 25-37.
- Isaka, M., Yasuda, Y., Mizokami, M., Kozuka, S., Taniguchi, T., Matano, K., Maeyama, J.-I., Mizuno, K., Morokuma, K., Ohkuma, K., Goto, N., Tochikubo, K., 2001.** Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant. *Vaccine* 19(11-12), 1460-1466.
- Ishikawa, F., Katsura, M., Tamai, I., Tsuji, A., 2001.** Improved nasal bioavailability of elcatonin by insoluble powder formulation. *Int. J. Pharm.* 224, 105-114.
- Ishikawa, F., Murano, M., Hiraishi, M., Yamaguchi, T., Tamai, I., Tsuji, A., 2002.** Insoluble powder formulation as an effective nasal drug delivery system. *Pharm. Res.* 19, 1097-1104.
- Izumrudov, V.A., Zhiryakova, M.V., 1999.** Stability of DNA-containing interpolyelectrolyte complexes in water-salt solutions. *Macromol. Chem. Phys.* 200, 2533-2540.
- Jabbal-Gill, I., Lin, W., Kistner, O., Davis, S.S., Illum, L., 2001.** Polymeric lamellar substrate particles for intranasal vaccination. *Adv. Drug Deliv. Rev.* 51, 97-111.
- Janaswamy, S., Chandrasekaran, R., 2001.** Three-dimensional structure of the sodium salt of iota-carrageenan. *Carbohydr. Res.* 335, 181-194.
- Jenkins, P.G., 1999.** Mucosal vaccine delivery. *Expert Opin. Ther. Pat.* 9(3), 255-262.
- Jensen, B., Matsson, L., 2002.** Oral versus rectal midazolam as a pre-anaesthetic sedative in children receiving dental treatment under general anaesthesia. *Acta Paediatr.* 91(8), 920-925.
- Jiao, Y., Ubrich, N., Marchand-Arvier, M., Vigneron, C., Hoffman, M., Lecompte, T., Maincent, P., 2002.** In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. *Circulation* 105(2), 230-235.
- Jones, N., Rog, D., 1998.** Olfaction: a review. *J. Laryngol. Otol.* 112(1), 11-24.
- Jones, N., 2001.** The nose and paranasal sinuses physiology and anatomy. *Adv. Drug Deliv. Rev.* 51, 5-19.
- Jones, D., Burt, D.S., Lowell, G.H., White, G.L., Rioux, C., 2002.** A novel proteosome-liposaccharide vaccine adjuvant. *PCT Int. Appl. WO 0272012.*
- Jung, B.H., Chung, B.C., Chung, S.J., Lee, M.H., Shim, C.K., 2000.** Prolonged delivery of nicotine in rats via nasal administration of proliposomes. *J. Contr. Rel.* 66, 73-79.
- Jung, B.H., Chung, S.J., Shim, C.K., 2002.** Proliposomes as prolonged intranasal drug delivery systems. *STP Pharma Sci.* 12, 33-38.
- Junginger, H.E., Verhoef, J.C., Merkus, F.W.H.M., 1991a.** Nasale Arzneiformen für die systemische Wirkstoffabsorption. *DAZ* 131(8), 295-303.
- Junginger, H.E., 1991b.** Mucoadhesive hydrogels. *Pharmazeutische Industrie* 53(11), 1056-1065.

- Junginger**, H.E., Hoogstraate, J.A., Verhoef, J.C., **1999**. Recent advances in buccal drug delivery and absorption – in vitro and in vivo studies. *J. Contr. Rel.* 62, 149-159.
- Kabasakalian**, P., Britt, E., Yudis, M.D., **1966**. Solubility of some steroids in water. *J. Pharm. Sci.* 55, 642.
- Kaliner**, M., Marom, Z., Patow, C., Shelhamer, J., **1984**. Human respiratory mucus. *J. Allergy Clin. Immun.* 73(3), 318-323.
- Kalra**, R., Khar, R.K., Ahuja, A., Ali, J., **2001**. Bilayered buccoadhesive wafers of an antihypertensive agent: formulation and evaluation. *Proc. Symp. Contr. Rel. Bioact. Mat.*, 644-645.
- Kararli**, T.T., Needham, T.E., Griffin, M., Schoenhard, G., Ferro, L.J., Alcorn, L., **1992a**. Oral delivery of a renin inhibitor compound using emulsion formulations. *Pharm. Res.* 9(7), 888-893.
- Kararli**, T.T., Needham, T.E., Baron, D.A., Schmidt, R.E., Katz, B., Belonio, B., **1992b**. Enhancement of nasal delivery of a renin inhibitor in the rat using emulsion formulations. *Pharm. Res.* 9(8), 1024-1028.
- Kashi**, S.D., Lee, V.H.L., **1986**. Enkephalin hydrolysis in homogenates of various absorptive mucosae of the albino rabbit: similarities in rates and involvement of aminopeptidases. *Life Sciences* 38(22), 2019-28.
- Kawaguchi**, Y., Nishiyama, T., Okada, M., Kamachi, M., Harada, A., **2000**. Complex formation of poly( $\epsilon$ -caprolactone) with cyclodextrins. *Macromolecules* 33, 4472-4477.
- Kawakami**, S., Nishida, K., Mukai, T., Yamamura, K., Nakamura, J., Sakaeda, T., Nakashima, M., Sasaki, H., **2001**. Controlled release and ocular absorption of tilisolol utilizing ophthalmic insert – incorporated lipophilic prodrugs. *J. Contr. Rel.* 76, 255-263.
- Kawashima**, Y., Yamamoto, H., Takeuchi, H., Fujioka, S., Hino, T., **1999**. Pulmonary delivery of insulin with nebulized dl-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. *J. Contr. Rel.* 62, 279-287.
- Kim**, C.S., Folinsbee, L.J., **1997**. Physiological and biomechanical factors relevant to inhaled drug delivery. In: Adjei, A.L., Gupta, P.K. (Eds.), *Inhalation delivery of therapeutic peptides and proteins*. Marcel Dekker Inc., New York, pp 3-25.
- Knowles**, M.R., Robinson, J.M., Wood, R.E., Pue, C.A., Mentz, W.M., Wager, G.C., Gatzky, J.T., Boucher, R.C., **1997**. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects. *J. Clin. Invest.* 100(10), 2588-2596.
- Ko**, K.-T., Needham, T.E., Zia, H., **1998**. Emulsion formulations of testosterone for nasal administration. *J. Microencapsul.* 15(2), 197-205.
- Koji**, D., **1998**. Aqueous suspension for nasal administration containing loteprednol etabonate. *PCT Int. Appl. WO* 9831343.
- Komase**, K., Tamura, S., Matsuo, K., Watanabe, K., Hattori, N., Odaka, A., Suzuki, Y., Kurata, T., Aizawa, C., **1998**. Mutants of *Escherichia coli* heat-labile enterotoxin as an adjuvant for nasal influenza vaccine. *Vaccine* 16(2-3), 248-254.
- Kriwet**, B., Kissel, T., **1995**. Poly(acrylic acid) microparticles widen the intercellular spaces in caco-2 cell monolayers. An examination by confocal laser scanning microscopy. *Eur. J. Pharm. Biopharm.* 42, 233-240.

- Kublik**, H., Vidgren, M.T., **1998**. Nasal delivery systems and their effect on deposition and absorption. *Adv. Drug Deliv. Rev.* 29, 157-177.
- Kuper**, F.C., Koornstra, P.J., Hameleers, D.M.H., Biewenga, J., Spit, B.J., Duijvestijn, A.M., van Breda Vriesman, P.J.C., Sminia, T., **1992**. The role of the nasopharyngeal lymphoid tissue. *Immunol. Today* 13(6), 219-224.
- Kurosawa**, N., Owada, E., Ito, K., **1998**. Avoidance of hepatic first-pass effect in the rabbit via rectal route of administration. *Biopharm. Drug Dispos.* 19(9), 589-594.
- Lai**, H.L., Abu'Khalil, A., Craig, D.Q.M., **2003**. The preparation and characterization of drug-loaded alginate and chitosan sponges. *Int. J. Pharm.* 251, 175-181.
- Lalka**, D., Griffith, R.K., Cronenberger, C.L., **1993**. The hepatic first-pass metabolism of problematic drugs. *J. Clin. Pharmacol.* 33(7), 657-69
- Langguth**, P., Bohner, V., Heizmann, J., Merkle, H.P., Wolfram, S., Amidon, G.L., Yamashita, S., **1997**. The challenge of proteolytic enzymes in intestinal peptide delivery. *J. Contr. Rel.* 46(1,2), 39-57.
- Langoth**, N., Kalbe, J., Bernkop-Schnürch, A., **2003**. Development of buccal drug delivery systems based on a thiolated polymer. *Int. J. Pharm* 252(1-2), 141-148.
- Law**, S.L., Huang, K.J., Chou, H.Y., **2000**. Effects of liposomes on calcitonin penetration through nasal mucosa. *Proc. Symp. Contr. Rel. Bioact. Mat.*, 285-286.
- Law**, S.L., Huang, K.J., Chou, H.Y., **2001**. Preparation of desmopressin-containing liposomes for intranasal delivery. *J. Contr. Rel.* 70, 375-382.
- Le Boursais**, C.A., Treupel-Acar, L., Rhodes, C.T., Sado, P.A., Leverage, R., **1995**. New ophthalmic drug delivery systems. *Drug Dev. Ind. Pharm.* 21(1), 19-59.
- Le Questel**, J-Y., Cros, S., Mackie, W., Pérez, S., **1994**. Computer modeling of sulphated carbohydrates: application to carrageenans. *Int. J. Macromol.* 17(3-4), 161-175.
- Leclercq**, L., Bria, M., Morcellet, M., Martel, B., **1998**.  $\beta$ -cyclodextrin-polyelectrolyte interactions in aqueous solution: I. Poly(4-sodium styrenesulfonate) (NaPSS). *J. Inclus. Phenom. Mol.* 30(3), 215-225.
- Lee**, S.W., Hardy, J.G., Wilson, C.G., Smelt, G.J.C., **1984**. Nasal sprays and polyps. *Nucl. Med. Commun.* 5, 697-703.
- Lee**, V.H.L., Yamamoto, A., **1990**. Penetration and enzymic barriers to peptide and protein absorption. *Adv. Drug Deliv. Rev.* 4(2), 171-207.
- Lee**, J.W., Park, J.H., Robinson, J.R., **2000**. Bioadhesive dosage forms: The next generation. *J. Pharm. Sci.* 89, 850-866.
- Lee**, Y.-C., Simamora, P., Pinsuwan, S., Yalkowsky, S.H., **2002**. Review on the systemic delivery of insulin via the ocular route. *Int. J. Pharm.* 233, 1-18.
- Lejus**, C., Renaudin, M., Testa, S., Malinovsky, J.M., Vigier, T., Souron, R., **1997**. Midazolam for premedication in children: nasal vs. rectal administration. *Eur. J. Anaesth.* 14(3), 244-249.
- Lemoine**, D., Deschuyteneer, M., Hogge, F., Preat, V., **1999**. Intranasal immunization against influenza virus using polymeric particles. *J. Biomat. Sci. – Polym. E.* 10(8), 805-825.
- Lewin**, M.R., Chowcat, N.L., Jayaraj, A.P., Boulos, P.B., **1986**. Collagenase inhibition in colonic mucosa by proteinase inhibitors. *Brit. J. Exp. Pathol.* 67(4), 523-526.

- Li, L., Nandi, I., Kim, K.H., 2002.** Development of an ethyl laurate-based microemulsion for rapid-onset intranasal delivery of diazepam. *Int. J. Pharm.* 237, 77-85.
- Lii, C., Chen, C.-H., Yeh, A., Lai, V.M.-F., 1999.** Preliminary study on the degradation kinetics of agarose and carrageenans by ultrasound. *Food Hydrocolloids* 13, 477-481.
- Lo Nostro, P., Lopes, J.R., Ninham, B.W., Baglioni, P., 2002.** Effect of cations and anions on the formation of polypseudorotaxanes. *J. Phys. Chem. B* 106, 2166-2174.
- Loftsson, T., Masson, M., 2001.** Cyclodextrins in topical drug formulations: theory and practice. *Int. J. Pharm.* 225, 15-30.
- Lohikangas, L., Wilen, M., Einarsson, M., Artursson, P., 1994.** Effects of a new lipid-based drug delivery system on the absorption of low molecular weight heparin (Fragmin) through monolayers of human intestinal epithelial Caco-2 cells and after rectal administration to rabbits. *Eur. J. Pharm. Sci.* 1(6), 297-305.
- Lueßen, H.L., Verhoef, J.C., Borchard, G., Lehr, C.-M., de Boer, A.G., Junginger, H.E., 1995.** Mucoadhesive polymers in peroral peptide delivery. II. Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. *Pharm. Res.* 12, 1293-1298.
- Luk, C.K., Dulfano, M., 1983.** Effect of pH, viscosity and ionic-strength changes on ciliary beating frequency of human bronchial explants. *Clin. Sci.* 64(4), 449-451.
- Lux, A., Maier, S., Dinslage, S., Süverkrüp, R., Diestelhorst, M., 2003.** A comparative bioavailability study of three conventional eye drops versus a single lyophilisate. *Brit. J. Ophthalmol.* 87(4), 436-440.
- MacLaughlin, F.C., Mumper, R.J., Wang, J., Tagliaferri, J.M., Gill, I., Hinchcliffe, M., Rolland, A.P., 1998.** Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. *J. Contr. Rel.* 56(1-3), 259-272.
- Madara, J.L., Dharmasathaphorn, K., 1985.** Occluding junction structure function relationship in a cultured epithelial monolayer. *J. Cell. Biol.* 101, 2124-2133.
- Madsen, F., Eberth, K., Smart, J.D., 1998.** A rheological examination of the mucoadhesive/mucus interaction: the effect of mucoadhesive type and concentration. *J. Contr. Rel.* 50(1-3), 167-78.
- Maitani, Y., Asano, S., Takahashi, S., Nakagaki, M., Nagai, T., 1992.** Permeability of insulin entrapped in liposome through the nasal mucosa of rats. *Chem. Pharm. Bull.* 40, 1569-1572.
- Majima, Y., Harada, T., Shimizu, T., Takeuchi, K., Sakakura, Y., Yoshinaga, S., 1999.** Effect of biochemical components on rheologic properties of nasal mucus in chronic sinusitis. *Am. J. Respir. Crit. Care Med.* 160, 421-426.
- Malcolmson, R.J., Embleton, J.K., 1998.** Dry powder formulations for pulmonary drug delivery. *Pharm. Sci. Technol. To.* 1(9), 394-398.
- Martini, A., Muggetti, L., Warchol, M.P., 2000.** Nasal and pulmonary drug delivery systems. *Expert Opin. Ther. Pat.* 10(3), 315-323.
- Marttin, E., Verhoef, J.C., Romeijn, S.G., Merkus, F.W.H.M., 1995.** Effects of absorption enhancers on rat nasal epithelium in vivo: Release of marker compounds in the nasal cavity. *Pharm. Res.* 12 (8), 1151-1157.

- Marttin**, E., Romeijn, S.G., Verhoef, J.C., Merkus, F.W.H.M., **1997**. Nasal absorption of dihydroergotamine from liquid and powder formulations in rabbits. *J. Pharm. Sci.* 86(7), 802-807.
- Marttin**, E., Schipper, N.G.M., Verhoef, J.C., Merkus, F.W.H.M., **1998**. Nasal mucociliary clearance as a factor in nasal drug delivery. *Adv. Drug Deliv. Rev.* 29, 13-38.
- Matsuo**, K., Yoshikawa, T., Asanuma, H., Iwasaki, T., Hagiwara, Y., Chen, Z., Kadowaki, S.-E., Tsujimoto, H., Kurata, T., Tamura, S.-I., **2000**. Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin). *Vaccine* 18(24), 2713-2722.
- Maurizi**, M., Plaudetti, G., Todisco, T., Almadori, G., Ottavini, F., Zappone, C., **1984**. Ciliary ultrastructure and nasal mucociliary clearance in chronic and allergic rhinitis. *Rhinology* 22(4), 233-240.
- McMartin**, C., Hutchinson, L.E., Hyde, R., Peters, G.E., **1987**. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. *J. Pharm. Sci.* 76(7), 535-540.
- McNeela**, E.A., O'Connor, D., Jabbal-Gill, I., Illum, L., Davis, S.S., Pizza, M., Peppoloni, S., Rappuoli, R., Mills, K.H.G., **2000**. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. *Vaccine* 19, 1188-1198.
- Merkle**, H.P., Wolany, G.J.M., **1992**. Buccal delivery of peptide drugs. *J. Contr. Rel.* 21, 155-164.
- Merkus**, F.W.H.M., Schipper, N.G.M., Hermens, W.A.J.J., Romeijn, S.G., Verhoef, J.C., **1993**. Absorption enhancers in nasal drug delivery: efficacy and safety. *J. Contr. Rel.* 24, 201-208.
- Merkus**, F.W.H.M., Verhoef, J.C., **1994**. Nasal drug delivery: Trends and Perspectives. In: Swarbrick, J., Boylan, J.C. (Eds.), *Encyclopedia of pharmaceutical technology*, Vol. 10, Marcel Dekker Inc., New York, pp. 191-220.
- Mestecky**, J., Moldoveanu, Z., Michalek, S.M., Morrow, C.D., Compans R.W., Schafer, D.P., Russell, M.W., **1997**. Current options for vaccine delivery by mucosal routes. *J. Contr. Rel.* 48, 243-257.
- Middleton**, P.G., Geddes, D.M., Alton, E.W., **1993**. Effect of amiloride and saline on nasal mucociliary clearance and potential difference in cystic fibrosis and normal subjects. *Thorax* 48(8), 812-816.
- Miyamoto**, M., Natsume, H., Satoh, I., Ohtake, K., Yamaguchi, M., Kobayashi, D., Sugibayashi, K., Morimoto, Y., **2001**. Effect of poly-L-arginine on the nasal absorption of FITC-dextran of different molecular weights and recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats. *Int. J. Pharm.* 226, 127-138.
- Miyazaki**, S., Suisha, F., Kawasaki, N., Shirakawa, M., Yamatoya, K., Attwood, D., **1998**. Thermally reversible xyloglucan gels as vehicles for rectal drug delivery. *J. Contr. Rel.* 56, 75-83.
- Morimoto**, K., Morisaka, K., Kamada, A., **1985**. Enhancement of nasal absorption of insulin and calcitonin using polyacrylic acid gel. *J. Pharm. Pharmacol.* 37, 134-136.

- Morimoto, K., Yamaguchi, H., Iwakura, Y., Morisaka, K., Ohashi, Y., Nakai, Y., 1991.** Effects of viscous hyaluronate-sodium solutions on the nasal absorption of vasopressin and an analogue. *Pharm. Res.* 8, 471-474.
- Morimoto, K., Miyazaki, M., Kakemi, M., 1995.** Effects of proteolytic enzyme inhibition on nasal absorption of salmon calcitonin in rats. *Int. J. Pharm.* 133, 1-8.
- Mowat, A.M., Donachie, A.M., 1991.** ISCOMS – a novel strategy for mucosal immunization? *Immunol. Today* 12, 383-385.
- Muramatsu, K., Maitani, Y., Takayama, K., Nagai, T., 1999.** The relationship between the rigidity of the liposomal membrane and the absorption of insulin after nasal administration of liposomes modified with absorption enhancers containing insulin in rabbits. *Drug Dev. Ind. Pharm.* 25, 1099-1105.
- Mygind, N., Dahl, R., 1998.** Anatomy, physiology and function of the nasal cavity in health and disease. *Adv. Drug Deliv. Rev.* 29, 3-12.
- Nagai, T., Nishimoto, Y., Nambu, N., Suzuki, Y., Sekine, K., 1984.** Powder dosage form of insulin for nasal administration. *J. Contr. Rel.* 1, 15-22.
- Nakamura, F., Ohta, R., Machida, Y., Nagai, T., 1996.** In vitro and in vivo nasal mucoadhesion of some water-soluble polymers. *Int. J. Pharm.* 134, 173-181.
- Nakamura, K., Maitani, Y., Lowman, A.M., Takayama, K., Peppas, N.A., Nagai, T., 1999.** Uptake and release of budesonide from mucoadhesive pH-sensitive copolymers and their application to nasal delivery. *J. Contr. Rel.* 61, 329-335.
- Nally, J.E., Artiushin, S., Sheoran, A.S., Burns, P.J., Simon, B., Gilley, R.M., Gibson, J., Sullivan, S., Timoney, J.F., 2001.** Induction of mucosal and systemic antibody specific for SeMF3 of *Streptococcus equi* by intranasal vaccination using sucrose acetate isobutyrate based delivery system. *Vaccine* 19, 492-497.
- Natsume, H., Ikawa, S., Ohtake, K., Miyamoto, M., Yamaguchi, M., Hosoya, K.-I., Kobayashi, D., Sugibayashi, K., Morimoto, Y., 1999.** Screening of cationic compounds as an absorption enhancer for nasal drug delivery. *Int. J. Pharm.* 185, 1-12.
- Nilsson, S., 1995.** Interactions between water-soluble cellulose derivatives and surfactants: 1. The HPMC/SDS/water system. *Macromolecules* 28, 7837-7844.
- Oechslein, C.R., Fricker, G., Kissel, T., 1996.** Nasal delivery of octreotide: Absorption enhancement by particulate carrier systems. *Int. J. Pharm.* 139, 25-32.
- Okimoto, K., Ohike, A., Ibuki, R., Aoki, O., Ohnishi, N., Irie, T., Uekama, K., Rajewski, R.A., Stella, V.J., 1999.** Design and evaluation of an osmotic pump tablet (OPT) for chlorpromazine using (SBE) $\gamma$ -m- $\beta$ -CD. *Pharm. Res.* 16(4), 549-54.
- Östh, K., Paulsson, M., Björk, E., Edsman, K., 2002.** Evaluation of drug release from gels on pig nasal mucosa in a horizontal Ussing chamber. *J. Contr. Rel.* 83, 377-388.
- Partidos, C.D., 2000.** Intranasal vaccines: forthcoming challenges. *PSTT* 3(8), 273-281.
- Pauletti, G.M., Gangwar, S., Siahaan, T.J., Aube, J., Borchardt, R.T., 1997.** Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies. *Adv. Drug Deliv. Rev.* 27(2,3), 235-256.
- Pelissier, C., de Kervasdoué, A., Chuong, V.T., Maudis, E.-L., Valleteau de Mouillac, F., Breil, M.-H., Moniot, G., Zeitoun-Lepvrier, G., Robin, M., Rime, B., 2001.** Clinical evaluation, dose-finding and acceptability of AERODIOL<sup>®</sup>, the pulsed estrogen therapy for the treatment of climacteric symptoms. *Maturitas* 37, 181-189.

- Pennington**, A.K., Ratcliffe, J.H., Wilson, C.G., Hardy, J.G., **1988**. The influence of solution viscosity on nasal spray deposition and clearance. *Int. J. Pharm.* 43, 221-224.
- Peppas**, N.A., Buri, P.A., **1985**. Surface, interfacial and molecular aspects of polymer bioadhesion on soft tissue. *J. Contr. Rel.* 2, 257-275.
- Peppas**, N.A., Khare, A.R., **1993**. Preparation, structure and diffusional behavior of hydrogel in controlled release. *Adv. Drug Deliv. Rev.* 11, 1-35.
- Pereswetoff-Morath**, L., Edman, P., **1995a**. Influence of osmolarity on nasal absorption of insulin from the thermogelling polymer ethyl(hydroxyethyl)cellulose. *Int. J. Pharm.* 125, 205-213.
- Pereswetoff-Morath**, L., Edman, P., **1995b**. Dextran microspheres as a potential nasal drug delivery system for insulin – in vitro and in vivo properties. *Int. J. Pharm.* 124, 37-44.
- Pereswetoff-Morath**, L., **1998**. Microspheres as nasal drug delivery systems. *Adv. Drug Deliv. Rev.* 29, 185-194.
- Perry**, M., Whyte, A., **1998**. Immunology of the tonsils. *Immunol. Today* 19(9), 414-421.
- Persson**, B., Nilsson, S., Sundeloef, L.-O., **1996**. On the characterization principles of some technically important water-soluble nonionic cellulose derivatives. Part II: Surface tension and interaction with a surfactant. *Carbohydr. Polym.* 29(2), 119-127.
- Petruson**, B., Hansson, H.A., Karlsson, G., **1984**. Structural and functional aspects of cells in the nasal mucociliary system. *Archiv. Otolaryngol.* 110(9), 576-581.
- Pezron**, I., Tirucherai, G.S., Duvvuri, S., Mitra, A.K., **2002**. Prodrug strategies in nasal drug delivery. *Expert. Opin. Ther. Pat.* 12(3), 331-340.
- Phillpotts**, R.J., Davies, H.W., Willman, J., Tyrrell, D.A.J., Higgins, P.G., **1984**. Pharmacokinetics of intranasally applied medication during a cold. *Antivir. Res.* 4(1-2), 71-74.
- Plante**, M., Jones, T., Allard, F., Torossian, K., Gauthier, J., St-Felix, N., White, G.L., Lowell, G.H., Burt, D.S., **2001**. Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge. *Vaccine* 20(1-2), 218-225.
- Ponchel**, G., Touchard, F., Duchene, D., Peppas, N.A., **1987**. Bioadhesive analysis of controlled release systems. I. Fracture and interpenetration analysis in poly(acrylic acid)-containing systems. *J. Contr. Rel.* 5, 129-141.
- Pontiroli**, A.E., Calderara, A., Pozza, G., **1989**. Intranasal drug delivery: potential advantages and limitations from a clinical pharmacokinetic perspective. *Clin. Pharm.* 17, 209-307.
- Proctor**, D.F., Lundqvist, G., **1973**. Clearance of inhaled particles from the human nose. *Arch. Intern. Med.* 131(1), 132-139.
- Puttipipatkachorn**, S., Nunthanid, J., Yamamoto, K., Peck, G.E., **2001**. Drug physical state and drug-polymer interaction on drug release from chitosan matrix films. *J. Contr. Rel.* 75, 143-153.
- Qiu**, Y., Gupta, P.K., Adjei, A.L., **1997**. Absorption and bioavailability of inhaled peptides and proteins. In: Adjei, A.L., Gupta, P.K. (Eds.), *Inhalation delivery of therapeutic peptides and proteins*. Marcel Dekker Inc., New York, pp 89 -131.
- Quraishi**, M.S., Jones, N.,S., Mason, J., **1998**. The rheology of nasal mucus: a review. *Clin. Otolaryngol.* 23(5), 403-413.



- Raghavan**, C.V., Muthulingam, C., Jenita, J.A.J.L., Ravi, T.K., **2002**. An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting. *Chem. Pharm. Bull.* 50(7), 892-895.
- Ray**, R., Glaze, B.J., Moldoveanu, Z., Compans, R.W., **1985**. Intranasal immunization with envelop glycoproteins of human parainfluenza virus type 3. *J. Infect. Dis.* 157, 648-654.
- Rebelatto**, M.C., Guimond, P., Bowersock, T.L., Hogenesch, H., **2001**. Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles. *Vet. Immunol. Immunop.* 83(1-2), 93-105.
- Rojanaskul**, Y., Wang, L.-Y., Baht, M., Glover, D.D., Malanga, C.J., Ma, J.K.H., **1992**. The transport barrier of epithelia: A comparative study on membrane permeability and charge selectivity in the rabbit. *Pharm. Res.* 9(8), 1029-1034.
- Rudin**, A., Riise, G.C., Holmgren, J., **1999**. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. *Infect. Immun.* 67, 2884-2890.
- Rydén**, L., Edman, P., **1992**. Effect of polymers and microspheres on the nasal absorption of insulin in rats. *Int. J. Pharm.* 83, 1-10.
- Sachdeva**, A., Sachdeva, O.P., Gulati, S.P., Kakkar, V. **1993**. Nasal mucociliary clearance and mucus pH in patients with diabetes mellitus. *Indian J. Med. Res.* 98(3), 265-268.
- Sakakura**, Y., Ukai, K., Majima, Y., Murai, S., Harada, T., Miyoshi, Y., **1983**. Nasal mucociliary clearance under various conditions. *Acta Otolaryngol.* 96(1-2), 167-173.
- Sakar**, M.A., **1992**. Drug metabolism in the nasal mucosa. *Pharm. Res.* 9 (1), 1-9.
- Schipper**, N.G.M., Verhoef, J.C., Merkus, F.W.H.M., **1991**. The nasal mucociliary clearance: Relevance to nasal drug delivery. *Pharm. Res.* 8(7), 807-814.
- Schramm**, G., **1995**. Einführung in Rheologie und Rheometrie. Gebrüder Haake GmbH, Karlsruhe, Germany, pp 156-183.
- Schreder**, S., Lee, G., **1996**. Water - a plasticizer for polymers? *Proc. Int. Symp. Contr. Rel. Bioact. Mat.*, 727-728.
- Shahin**, R., Leef, M., Eldridge, J., Hudson, M., Gilley, R., **1995**. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres. *Infect. Immun.* 63, 1195-1200.
- Shao**, Z., Mitra, A.K., **1994**. Bile salt – fatty acid mixed micelles as nasal absorption promoters. III. Effects on nasal transport and enzymatic degradation of acyclovir prodrugs. *Pharm. Res.* 11, 243-250.
- Sherrat**, A.J., Houdi, A.A., **2002**. Compositions for enhanced nasal delivery of oxybutynin. *PCT Int. Appl. WO 0217907*.
- Shimoda**, N., Igusa, K., **1987**. Antianemic nasal-bed gel containing human erythropoietin. *Ger. Offen. DE 3618561*.
- Shojaei**, A.H., **1998**. Buccal mucosa as a route for systemic drug delivery: A review. *J. Pharm. Pharm. Sci.* 1(1), 15-30.
- Simamora**, P., Nadkarni, S.R., Lee, Y.-C., Yalkowsky, S.H., **1998**. Controlled delivery of pilocarpine. 2. In-vivo evaluation of the Gelfoam<sup>®</sup> device. *Int. J. Pharm.* 170, 209-214.

- Sinswat**, P., Tengamnuay, P., **2003**. Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl- and dimethyl- $\beta$ -cyclodextrins. *Int. J. Pharm.* 257, 15-22.
- Singh**, M., Briones, M., O'Hagan, D.T., **2001**. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. *J. Contr. Rel.* 70, 267-276.
- Sinha**, V.R., Kumria, R., **2001**. Polysaccharides in colon-specific drug delivery. *Int. J. Pharm.* 224(1-2), 19-38.
- Sinyakov**, M.S., Kharitononkov, I.G., Arefev, I.M., Eskov, A.P., **1980**. Influenza virus hemagglutinin: hydrodynamic properties and molecular weight. *Voprosy Virusologii* 1, 42-45.
- Skehel**, J.J., Bayley, P.M., Brown, E.B., Martin, S.R., Waterfield, M.D., White, J.M., Wilson, I.A., Wiley, D.C., **1982**. Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. *Proc. Natl. Acad. Sci. USA* 79(4), 968-972.
- Sleigh**, M.A., Blake, J.R., Liron, N., **1988**. The propulsion of mucus by cilia. *Am. Rev. Respir. Dis.* 137(3), 726-741.
- Smart**, J.D., **1999**. The role of water movement and polymer hydration in mucoadhesion. In: Mathiowitz, E., Chickering, D.E., Lehr, C.-M. (Eds.), *Bioadhesive drug delivery systems. Fundamentals, novel approaches, and development*, Marcel Dekker Inc., New York, pp. 11-23.
- Soane**, R.J., Frier, M., Perkins, A.C., Jones, N.S., Davis, S.S., **1999**. Evaluation of the clearance characteristics of bioadhesive systems in humans. *Int. J. Pharm.* 178, 55-65.
- Soane**, R.J., Hinchcliffe, M., Davis, S.S., Illum, L., **2001**. Clearance characteristics of chitosan based formulations in the sheep nasal cavity. *Int. J. Pharm.* 217, 183-191.
- Sokol**, R.Z., Okuda, H., Stanczyk, F.Z., Wolfe, G.W., Delaney, J.C., Chapin, R.E., **1999**. Normative reproductive indices for male and female adult Sprague-Dawley rats. *Contraception* 59, 203-207.
- Stockwell**, A.F., Davis, S.S., Walker, S.E., **1986**. In vitro evaluation of alginate gel systems as sustained release drug delivery systems. *J. Contr. Rel.* 3(2-3), 167-75.
- Striebel**, H.W., Kramer, J., Luhmann, I., Rohierse-Hohler, I., Rieger, A., **1993**. Pharmakokinetische Studie zur intranasalen Gabe von Fentanyl. *Der Schmerz* 7, 122-125.
- Suman**, J.D., Laube, B.L., Dalby, R., **1999**. Comparison of nasal deposition and clearance of aerosol generated by a nebulizer and an aqueous spray pump. *Pharm. Res.* 16(19), 1648-1652.
- Suzuki**, Y., Makino, Y., **1999**. Mucosal drug delivery using cellulose derivatives as a functional polymer. *J. Contr. Rel.* 62, 101-107.
- Taeko**, A., Yoshie, M., Tomonaga, Y., Kozo, T., Tsuneji, N., **1998**. Nasal insulin delivery in rabbits using soybean-derived steryl glycoside and sterol mixtures as novel enhancers in suspension dosage forms. *Biol. Pharm. Bull.* 21, 862-865.
- Takeuchi**, H., Yamamoto, H., Kawashima, Y., **2001**. Mucoadhesive nanoparticulate systems for peptide drug delivery. *Adv. Drug Deliv. Rev.* 47, 39-54.

- Takenaga**, M., Serizawa, Y., Azechim, Y., Ochiai, A., Kosaka, Y., Igarashi, R., Mizushima, Y., **1998**. Microparticle resins as a potential drug delivery system for insulin. *J. Contr. Rel.* 52, 81-87.
- Taki**, Y., Sakane, T., Nadai, T., Sezaki, H., Amidon, G.L., Langguth, P., Yamashita, S., **1998**. First-pass metabolism of peptide drugs in rat perfused liver. *J. Pharm. Pharmacol.* 50(9), 1013-1018.
- Tam**, J., Fiegel, J., Hanes, J., **2001**. Protein crystals for pulmonary controlled drug delivery. *Proc. Int. Symp. Contr. Rel. Bioact. Mater.*, 1027-1028.
- Taylor**, A.E., Gaar, K.A., **1970**. Estimation of equivalent pore radii of pulmonary capillary and alveolar membranes. *Am. J. Physiol.* 218, 1133-1140.
- Tengamnuay**, P., Mitra, A.K., **1990a**. Bile salt – fatty acid mixed micelles as nasal absorption promoters of peptides. I. Effects of ionic strength, adjuvant composition, and lipid structure on nasal absorption of [D-Arg<sup>2</sup>]Kyotorphin. *Pharm. Res.* 7, 127-133.
- Tengamnuay**, P., Mitra, A.K., **1990b**. Bile salt – fatty acid mixed micelles as nasal absorption promoters of peptides. II. In vivo nasal absorption of insulin in rats and effects of mixed micelles on the morphological integrity of the nasal mucosa. *Pharm. Res.* 7, 370-375.
- Tengamnuay**, P., Sahamethapat, A., Sailasuta, A., Mitra, A.K., **2000**. Chitosan as nasal absorption enhancer of peptides: comparison between free amine chitosans and soluble salts. *Int. J. Pharm.* 197, 53-67.
- Teshima**, D., Yamauchi, A., Makino, K., Kataoka, Y., Arita, Y., Nawata, H., Oishi, R., **2002**. Nasal glucagons delivery using microcrystalline cellulose in healthy volunteers. *Int. J. Pharm.* 233, 61-66.
- Teunissen**, M.W.E., Kleinbloesem, C.H., De Leede, L.G.J., Breimer, D.D., **1985**. Influence of cimetidine on steady state concentration and metabolite formation from antipyrine infused with a rectal osmotic mini pump. *Eur. J. Clin. Pharmacol.* 28, 681-684.
- Thanou**, M., Florea, B.I., Langemeyer, M.W.E., Verhoef, J.C., Junginger, H.E., **2000**. N-trimethylated chitosan chloride (TMC) improves the intestinal permeation of the peptide drug busserelin in vitro (caco-2 cells) and in vitro (rats). *Pharm. Res.* 17, 27-31.
- Tilney**, N.L., **1971**. Patterns of lymphatic drainage in the adult laboratory rat. *J. Anat.* 109, 369–383.
- Tirucherai**, G.S., Yang, C., Mitra, A.K., **2001**. Prodrug in nasal drug delivery. *Expert. Opin. Ther. Pat.* 1(1), 49-66.
- Togias**, A.G., Proud, D., Lichtenstein, L.M., Adams, G.K., Norman, P.S., Kagey-Sobotka, A., Naclerio, R.M., **1988**. The osmolality of nasal secretions increases when inflammatory mediators are released in response to inhalation of cold, dry air. *Am. Rev. Respir. Dis.* 137(3), 625-629.
- Tos**, M., **1983**. Distribution of mucus producing elements in the respiratory tract. Differences between upper and lower airway. *Eur. J. Respir. Dis. Suppl.* 128, 269-279.
- Ugwoke**, M.I., Sam, E., Van Den Mooter, G., Verbeke, N., Kinget, R., **1999**. Nasal mucoadhesive delivery system of the anti-parkinsonian drug apomorphin: influence of drug loading on in vitro and in vivo release in rabbits. *Int. J. Pharm.* 181, 125-138.

- Ugwoke**, M.I., Agu, R.U., Vanbilloen, H., Baetens, J., Augustijns, P., Verbeke, N., Mortelmans, L., Verbruggen, A., Kinget, R., Bormans, G., **2000**. Scintigraphic evaluation in rabbits of nasal drug delivery systems on Carbopol 971P and carboxymethylcellulose. *J. Contr. Rel.* 68, 207-214.
- Valenta**, C., Marschutz, M., Egyed, C., Bernkop-Schnürch, A., **2002**. Evaluation of the inhibition effect of thiolated poly(acrylates) on vaginal membrane bound aminopeptidase N and release of the model drug LH-RH. *J. Pharm. Pharmacol.* 54(5), 603-610.
- van de Donk**, H.J., Zuidema, J., Merkus, F.W.H.M., **1980a**. The influence of the pH and osmotic pressure upon tracheal ciliary beat frequency as determined with a new photo-electric registration device. *Rhinology* 18(2), 93-104.
- van de Donk**, H.J., Muller-Plantema, I.P., Zuidema, J., Merkus, F.W.H.M., **1980b**. The effects of preservatives on the ciliary beat frequency of chicken embryo tracheas. *Rhinology* 18(3), 119-33.
- van de Weert**, M., Hennink, W.E., Jiskoot, W., **2000**. Protein instability in poly(lactic-co-glycolic acid) microparticles. *Pharm. Res.* 17(10), 1159-1167.
- van der Lubben**, I.M., Kersten, G., Fretz, M.M., Beuvery, C., Verhoef, J.C., Junginger, H.E., **2003**. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. *Vaccine* 21(13-14), 1400-1408.
- Vanbever**, R., Mintzes, J.D., Wang, J., Nice, J., Chen, D., Batycky, R., Langer, R., Edwards, D.A., **1999**. Formulation and physical characterization of large porous particles for inhalation. *Pharm. Res.* 16 (11), 1735-1742.
- Vasir**, J.K., Tambwekar, K., Garg, S., **2003**. Bioadhesive microspheres as a controlled drug delivery system. *Int. J. Pharm.* 225, 13-32.
- Vaugelade**, C., Rohmer, A.-C., Burel, F., Belleney, J., Duclos, R., Bunel, C., **2001**. Progesterone freeze-dried systems in sublingual dosage forms. *Int. J. Pharm.* 229, 67-73.
- Vermani**, K., Garg, S., **2000**. The scope and potential of vaginal drug delivery. *Pharm. Sci Technol. To.* 3(10), 359-364.
- Vermehren**, C., Hansen, H.S., Thomsen, M.K., **1996**. Time dependent effects of two absorption enhancers on the nasal absorption of growth hormone in rabbits. *Int. J. Pharm.* 128(1,2), 239-50.
- Veuillez**, F., Kalia, Y.N., Jacques, Y., Deshusses, J., Buri, P., **2001**. Factors and strategies for improving buccal absorption of peptides. *Eur. J. Pharm. Biopharm.* 51, 93-109.
- Viebke**, C., Borgström, J., Piculell, L., **1995**. Characterization of kappa- and iota-carrageenan coils helices by MALLS/GPC. *Carbohydr. Polym.* 27, 145-154.
- Visor**, G.C., Bajka, E., Benjamin, E., **1986**. Intranasal delivery of nifedipine in rats. *J. Pharm. Sci.* 75, 44-46.
- Walle**, T., Walle, U.K., Olanoff, L.S., **1985**. Quantitative account of propranolol metabolism in urine of normal man. *Drug Metab. Dispos.* 13(2), 204-209.
- Walzer**, G.F., Langoth, N., Bernkop-Schnürch, A., **2002**. Peptidase activity on the surface of the porcine buccal mucosa. *Int. J. Pharm.* 233, 141-147.
- Wang**, W., **1999**. Instability, stabilization and formulation of liquid protein pharmaceuticals. *Int. J. Pharm.* 185, 129-188.

- Warshaw**, A.L., Bellini, C.A., Walker, W.A., **1977**. The intestinal mucosal barrier to intact antigenic protein. Difference between colon and small intestine. *Am. J. Surg.* 133(1), 55-58.
- Washington**, N., Steele, R.J.C., Jackson, S.J., Bush, D., Mason, J., Gill, D.A., Pitt, K., Rawlins, D.A., **2000a**. Determination of baseline human nasal pH and the effect of intranasally administered buffers. *Int. J. Pharm.* 198, 139-146.
- Washington**, N., McGlashan, J.A., Jackson, S.J., Bush, D., Pitt, K.G., Rawlins, D.A., Gill, D.A., **2000b**. The effect of nasal patency on the clearance of radiolabeled saline in healthy volunteers. *Pharm. Res.* 17(6), 733-736.
- Watts**, P.J., Illum, L., **1996**. Drug delivery composition containing chitosan or its derivatives having a defined zeta-potential. *PCT Int. Appl.* WO 9605810.
- Watts**, P.J., Illum, L., **1998a**. Gels for delivery of drugs to mucosal surfaces. *PCT Int. Appl.* WO 9847535.
- Watts**, P.J., Illum, L., **1998b**. Chitosan-gelatin A microparticles. *PCT Int. Appl.* WO 9830207.
- Watts**, P.J., Illum, L., **2001**. Composition for the administration of a DL-agonist. *US Patent* US 6310089.
- Weis**, W., Brown, J.H., Cusack, S., Paulson, J.C., Skehel, J.J., Wiley, D.C., **1988**. Structure of the influenza virus hemagglutinin complexed with its receptor, sialic acid. *Nature* 333, 426-31.
- Werner**, U., Bodmeier, R., **2002**. Development of a simple in vitro bioadhesion test for fast disintegrating nasal inserts. *Arch. Pharm.* 335 (Suppl.1), 124.
- Weyenberger**, W., Vermeire, A., Remon, J.P., Ludwig, A., **2003**. Characterization an in vivo evaluation of ocular bioadhesive minitables compressed at different forces. *J. Contr. Rel.* 89, 329-340.
- Wu**, H.Y., Nguyen, H.H., Russell, M.W., **1997**. Nasal lymphoid tissue (NALT) as a mucosal immune inductive site. *Scand. J. Immunol.* 46, 506-513.
- Yamamoto**, N., Sugimoto, M., Sakakibara, H., Saita, M., Shimozono, Y., Manako, T., **1992**. Pharmaceutical emulsion containing parathyroid hormone for pernasal administration. *Eur. Pat. Appl.* EP 471618.
- Yamamoto**, N., Sugimoto, M., Morimoto, S., Sakakibara, H., Saita, M., Shimozono, Y., Manako, T., **1993**. Pharmaceutical emulsion containing parathyroid hormone for pernasal administration. *PCT Int. Appl.* WO 9305805.
- Yamamoto**, A., Muranishi, S., **1997**. Rectal drug delivery systems: Improvement of rectal peptide absorption by absorption enhancers, protease inhibitors and chemical modification. *Adv. Drug Deliv. Rev.* 28, 275-299.
- Yamamoto**, A., Iseki, T., Ochi-Sugiyama, M., Okada, N., Fujita, T., Muranishi, S., **2001**. Absorption of water soluble compounds with different molecular weights and [ASU<sup>1.7</sup>]-eel calcitonin from various mucosal administration sites. *J. Contr. Rel.* 76, 363-374.
- Zaman**, M., McAllister, M., Martini, L.G., Lawrence, M.J., **1999**. The physico-chemical and biological factors influencing bioadhesion. *Biopharm Europe* (Sept.), 52-60.

- Zarzycki**, P.K., Lamparczyk, H., **1998**. The equilibrium constant of  $\beta$ -cyclodextrin-phenolphthalein complex: influence of temperature and tetrahydrofuran addition. *Journal of Pharmaceutical and Biomedical Analysis* 18, 165-170.
- Zhang**, W., Piculell, L., Nilsson, S., Knutsen, S.H., **1994**. Cation specificity and cation binding to low sulfated carrageenans. *Carbohydr. Polym.* 23, 105-110.
- Zhang**, Q., Shen, Z., Nagai, T., **2001**. Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. *Int. J. Pharm.* 218, 75-80.
- Zhou**, X.H., Li Wan Po, A., **1991a**. Peptide and protein drugs: I. Therapeutic applications, absorption and parenteral administration. *Int. J. Pharm* 75(2-3), 97-115.
- Zhou**, X.H., Li Wan Po, A., **1991b**. Peptide and protein drugs: II. Non-parenteral routes of delivery. *Int. J. Pharm* 75(2-3), 117-130.
- Zhou**, X.H., **1994**. Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs. *J. Contr. Rel.* 29, 239-252.
- Zia**, H., Dondeti, P., Needhman, T.E., **1993**. Intranasal drug delivery. *Clin. Res. Reg. Affairs* 10, 594-598.
- Zirinis**, P., **1995**. Nasal aqueous gels and pellets containing peptides. French Patent FR 2710529.